Illumina Acquires Grail To Accelerate Patient Access To Life-Saving Multi-Cancer Early-Detection Test
Illumina Acquires Grail To Accelerate Patient Access To Life-Saving Multi-Cancer Early-Detection Test
08/19/21, 12:01 AM
Location
menlo parkIllumina, Inc. (NASDAQ: ILMN) announced today that it has acquired GRAIL, a healthcare company focused on life-saving early detection of multiple cancers, but will hold GRAIL as a separate company during the European Commission's ongoing regulatory review.
Company Info
Company info
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit www.illumina.com and connect with us on Twitter, Facebook, LinkedIn, Instagram, and YouTube.
Investors:Brian Blanchett858.291.6421 IR@illumina.com
Media:Dr. Karen Birmingham646.355.2111 pr@illumina.com
Unlock Strategic Intelligence with Fundz
This is just a small preview. Unlock the full dataset of company insights, strategic events, and leadership shifts — all in one platform.
Trusted by sales, BD, and investment teams at Oracle, HubSpot, Affinity, and more.
Related people
CH
SH
EH
AH
JH
Trends
| Raised | Growth The data in the raised column shows reported funding for this location/industry over last 90 days. The data in the growth column indicates the % increase or decrease of the last 90 days vs. the previous 90 days. Please note: one or more large fundings, especially for a location/industry that doesn't historically receive much funding, can have a significant impact on the increase or decrease percentage. | |
|---|---|---|
| menlo park | $391.1 M | 42.2% |